United States · Series B startup

Who invested in TCR2

One round we have observed, with the 10 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$125Mraised across 1 round since 2018, from 1 source

Latest round
Series B, $125MMar 2018
Investors
10
See who backed them

The rounds

  1. Mar 2018

Everyone who backed them

Hill House CapitalFamily office1round
ArrowMark PartnersPrivate equity1round
Mirae AssetVC firm1round
Sirona CapitalVC firm1round
Syno CapitalVC firm1round
Haitong InternationalGrowth equity1round
LucionVC firm1round
Curative Ventures/ Redmileno record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

This firm lists TCR2 as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.

Mirae Asset Capital Life ScienceCorporate VCPer its own site

Quick answers about TCR2

Who invested in TCR2?

TCR2's investors include Hill House Capital, Alexandria Real Estate Equities, ArrowMark Partners, 6 Dimensions Capital and Mirae Asset, and 5 more on record.

How much has TCR2 raised?

TCR2 has raised $125M across 1 round since 2018.

When did TCR2 last raise?

TCR2's most recent round was a Series B of $125M in Mar 2018.

What was TCR2's biggest round?

Its most recent round, $125M in Mar 2018, is also its largest on record.

Who backed TCR2 first?

TCR2's first round on record, in Mar 2018, was backed by Hill House Capital, Alexandria Real Estate Equities and ArrowMark Partners and 7 others.

What stage is TCR2 at?

TCR2's latest named round is a Series B, in Mar 2018.

Where is TCR2 based?

TCR2 is based in the United States.

Companies like TCR2

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.